BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 38448909)

  • 1. An empirical ethics study of the coherence of NICE technology appraisal policy and its implications for moral justification.
    Charlton V; DiStefano M
    BMC Med Ethics; 2024 Mar; 25(1):28. PubMed ID: 38448909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ethical canary: narrow reflective equilibrium as a source of moral justification in healthcare priority-setting.
    Charlton V; DiStefano MJ
    J Med Ethics; 2024 Feb; ():. PubMed ID: 38373831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NICE and Fair? Health Technology Assessment Policy Under the UK's National Institute for Health and Care Excellence, 1999-2018.
    Charlton V
    Health Care Anal; 2020 Sep; 28(3):193-227. PubMed ID: 31325000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Justice, Transparency and the Guiding Principles of the UK's National Institute for Health and Care Excellence.
    Charlton V
    Health Care Anal; 2022 Jun; 30(2):115-145. PubMed ID: 34750743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does NICE apply the rule of rescue in its approach to highly specialised technologies?
    Charlton V
    J Med Ethics; 2022 Feb; 48(2):118-125. PubMed ID: 33685978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innovation as a value in healthcare priority-setting: the UK experience.
    Charlton V; Rid A
    Soc Justice Res; 2019; 32(2):208-238. PubMed ID: 31281204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The normative grounds for NICE decision-making: a narrative cross-disciplinary review of empirical studies.
    Charlton V
    Health Econ Policy Law; 2022 Oct; 17(4):444-470. PubMed ID: 35293306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
    Williams I; McIver S; Moore D; Bryan S
    Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Public Reasoning and Health-Care Priority Setting: The Case of NICE.
    Rumbold B; Weale A; Rid A; Wilson J; Littlejohns P
    Kennedy Inst Ethics J; 2017; 27(1):107-134. PubMed ID: 28366905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exorcising the positivist ghost in the priority-setting machine: NICE and the demise of the 'social value judgement'.
    Charlton V; Weale A
    Health Econ Policy Law; 2021 Oct; 16(4):505-511. PubMed ID: 33568251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Some inconsistencies in NICE's consideration of social values.
    Paulden M; O'Mahony JF; Culyer AJ; McCabe C
    Pharmacoeconomics; 2014 Nov; 32(11):1043-53. PubMed ID: 25145802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Financial interests of patient organisations contributing to technology assessment at England's National Institute for Health and Care Excellence: policy review.
    Mandeville KL; Barker R; Packham A; Sowerby C; Yarrow K; Patrick H
    BMJ; 2019 Jan; 364():k5300. PubMed ID: 30651227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK.
    de Folter J; Trusheim M; Jonsson P; Garner S
    Int J Technol Assess Health Care; 2018 Jan; 34(2):163-171. PubMed ID: 29633673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modifying NICE's Approach to Equity Weighting.
    Paulden M; McCabe C
    Pharmacoeconomics; 2021 Feb; 39(2):147-160. PubMed ID: 33517512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process.
    Schlander M
    J Med Ethics; 2008 Jul; 34(7):534-9. PubMed ID: 18591289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.
    Andronis L; Barton P; Bryan S
    Health Technol Assess; 2009 Jun; 13(29):iii, ix-xi, 1-61. PubMed ID: 19500484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can the NICE "end-of-life premium" be given a coherent ethical justification?
    Cookson R
    J Health Polit Policy Law; 2013 Dec; 38(6):1129-48. PubMed ID: 23974470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. At the center of health care policy making: the use of health technology assessment at NICE.
    Stevens AJ; Longson C
    Med Decis Making; 2013 Apr; 33(3):320-4. PubMed ID: 23519880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence.
    Littlejohns P; Barnett D; Longson C;
    Lancet Oncol; 2003 Apr; 4(4):242-50. PubMed ID: 12681268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
    Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
    Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.